← Patent-cliff monitor small molecule LIVMARLI MARALIXIBAT CHLORIDE
Loss of exclusivity October 2043 latest FDA-listed patent expiry
Drug detail Brand name LIVMARLI Active ingredient MARALIXIBAT CHLORIDE Strength EQ 30MG BASE Dosage form TABLET Route ORAL Modality Small molecule FDA approval April 2025 Marketing status RX
Listed patents Patent Expires Type 12296050 October 2043 product 11497745 February 2040 use U-4187 11229647 February 2040 use U-4187 11229661 October 2032 use U-4186 12350267 October 2032 use U-3973 10512657 October 2032 use U-4186 11376251 October 2032 use U-4187 11260053 May 2031 use U-4187
Regulatory exclusivity Code Expires I-938 March 2027 NCE September 2026
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.